ITGA2B and autoimmune thrombocytopenic purpura: In our cohort of adult ITP patients, we observed that the response to IVIg was more than five times higher in patients with newly diagnosed ITP (OR = 5.5) and up to five-fold higher in the presence of anti-GPIIb/IIIa antibodies (OR = 4.8), while secondary ITP were 10 times less prone to respond to IVIg (OR = 0.1).